Triple
T7930815
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | AbbVie |
E184183
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object |
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
|
E697099
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Venclexta | Statement: [AbbVie, notableProduct, Venclexta]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Venclexta Context triple: [AbbVie, notableProduct, Venclexta]
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Venclexta Triple: [AbbVie, notableProduct, Venclexta]
Generated description
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Venclexta Target entity description: Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca8290c21c8190906a5ca6fe2b03c4 |
completed | March 30, 2026, 2:02 p.m. |
| NER | Named-entity recognition | batch_69cb3accc388819087065ebe7d5d9591 |
completed | March 31, 2026, 3:09 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69cb5c01602081908ea1af24785260ff |
completed | March 31, 2026, 5:30 a.m. |
| NEDg | Description generation | batch_69cb5f22f89c8190a98208bf096a2427 |
completed | March 31, 2026, 5:44 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69cb76d2dff8819085ad9e10baad1537 |
completed | March 31, 2026, 7:25 a.m. |
Created at: March 30, 2026, 5:07 p.m.